RANCHO CORDOVA, Calif.,
Sept. 3, 2019 /PRNewswire/ -- Cesca
Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell
processing and autologous cell therapies for regenerative medicine,
today announced Jeff Cauble, Vice President of Finance and
Principal Accounting Officer, will present at the H.C. Wainwright
21st Annual Global Investment Conference on Tuesday, September 10 at 12:30 pm ET. The conference is being held
September 8-10 at the Lotte New York
Palace Hotel.
Management will also be available for one-on-one meetings with
institutional investors who are registered to attend the
conference. Institutional investors who would like to attend
Cesca's presentation or meet with management can register through
the H.C. Wainwright conference portal or contact Rx
Communications to schedule a meeting.
About Cesca Therapeutics Inc.
Cesca
Therapeutics develops, commercializes and markets a range of
automated technologies for CAR-T and other cell-based therapies.
Its device division, ThermoGenesis develops, commercializes and
markets a full suite of solutions for automated clinical
biobanking, point-of-care applications, and automation for
immuno-oncology. The company has developed an automated,
functionally-closed CAR-TXpress™ platform to streamline the
manufacturing process for the emerging CAR-T immunotherapy market.
For more information about Cesca,
please visit: www.CescaTherapeutics.com. For additional
information about ThermoGenesis, please
visit: www.thermogenesis.com.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula
Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/cesca-therapeutics-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300910094.html
SOURCE Cesca Therapeutics Inc.